Nephrology

Kidney failure is an enormous concern for people with T2D and DKD. This analysis confirms canagliflozin can slow its progression and have an impact on patients regardless of their level of kidney function.

FDA has approved a new treatment for diabetic kidney disease, which affects one in three patients with type 2 diabetes.

Last week I saw a patient who seemed to be losing control of her blood glucose levels. She had been doing well and her A1c had been around 6.0 - 6.3 for the past couple of years. She was doing this while only on metformin 1000 twice a day. She was referred to me by her physician because of high after-meal readings ranging up to 350 mg/dl. I went over her medical history and medications looking for a possible problem and found nothing.

Combined analysis of eGFR and albuminuria over 2 years has been shown to predict T2DM patients’ risk for major macrovascular outcomes.

Both patients and HCPs should be aware of early signs of kidney issues.

Diabetes mellitus is the leading cause of end-stage renal disease (ESRD) worldwide.

Study examines why type 2 diabetes incident rate is higher in patients with chronic kidney disease.

The PIONEER 5 study discusses the safety and efficacy of the first oral GLP-1 receptor agonist, a potential substitute to injections. 

The CARMELINA trial demonstrated noninferiority of linagliptin compared with placebo in CV events in high risk people with type 2 diabetes. 

Strong results motivate the ADA to update its Standard of Care for patients with diabetes.